Abstract
Hepatocyte growth factor (HGF) is known to be a potent mitogen and motogen for epithelial cells. Hepatocellular carcinoma (HCC) often metastasizes, and the c-Met/HGF receptor is highly expressed by HCC cells. The aim of this study was to investigate the signaling pathways associated with the motogenic effect of HGF on HCC cells via c-Met. HCC cell lines (Hep3B, HepG2, PLC, and Huh-7) and HCC cells harvested from patients were used for the Boyden chamber assay of chemotactic activity as well as for immunoprecipitation and immunoblotting studies. HGF stimulated the motility of Hep3B, HepG2, and Huh-7 cells in a dose-dependent manner in association with tyrosine phosphorylation of c-Met and activation of phosphatidylinositol 3-kinase (PI3-K). A tyrosine kinase inhibitor (genistein) and a PI3-K inhibitor (wortmannin) prevented the migration of HCC cells. However, migration was not prevented by calphostin C, an inhibitor of protein kinase C (PKC), which is a downstream target of phospholipase Cγ (PLCγ). HGF also stimulated the migration of HCC cells obtained from three patients, while wortmannin prevented the migration of these cells. These results indicate that HGF stimulates the migration of HCC cells through the tyrosine phosphorylation of c-Met via activation of PI3-K.
Similar content being viewed by others
References
Boros P, Miller CM. Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995; 345: 293–5.
Shiota G, Wang TC, Nakamura T et al. Hepatocyte growth factor in transgenic mice: effect on hepatocyte growth, liver regeneration and gene expression. Hepatology 1994; 19: 962–72.
Gherardi E, Stoker M, Perryman M et al. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc Natl Acad Sci USA 1989; 86: 5844–8.
Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA 1986; 83: 6489–93.
Montesano R, Schaller G, Orci L. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 1991; 66: 697–711.
Matsumoto K, Matsumoto K, Nakamura T et al. Hepatocyte growth factor/ scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 1994; 269: 31807–13.
Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996; 119: 591–600.
Bottaro DP, Rubin JS, Faletto DL et al. Identification of the hepatocyte growth factor as the c-met proto-oncogene product. Science 1991; 251: 802–4.
Di Renzo MF, Narsimhan RP, Olivero M et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6: 1997–2003.
Gonzatti-Haces M, Seth A, Park M et al. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein tyrosine kinase. Proc Natl Acad Sci USA 1989; 85: 21–5.
Pawson T. Protein modules and signaling networks. Nature 1995; 373: 573–80.
Zhu H, Naujokas MA, Fixman ED et al. Tyrosine 1356 in the carboxyl-terminal tail of the HGF/SF receptor is essential for the transduction of signal for cell motility and morphogenesis. J Biol Chem 1994; 269: 29943–48.
Ponzetto C, Bardelli A, Zhen Z et al. A multifunctional docking site mediates signaling and transduction by the hepatocyte growth factor/Scatter factor receptor family. Cell 1994; 77: 261–71.
Rodrigues GA, Park M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 1994; 9: 2019–27.
Royal I, Park M. Hepatocyte growth factor-induced scatter of madindarby canine kidney cells requires phosphatidylinositol 3–kinase. J Biol Chem 1995; 270: 27780–7.
Okuda K, Ohtsuki T, Obata H. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918–28.
Suzuki K, Hayashi N, Yamada Y et al. Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 1994; 20: 1231–6.
Ueki T, Fujimoto J, Suzuki T et al. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 1997; 25: 619–23.
Akiyama T, Ishida J, Nakagawa S et al. Genistein, a specific inhibitor of tyrosine specific protein kinases. J Biol Chem 1987; 262: 5592–5.
Yano H, Nakanishi S, Kimura K et al. Inhibition of histamine secretion by wortmannin through the blockage of phosphatidylinositol 3–kinase in RBL-2H3 cells. J Biol Chem 1993; 268: 25856–64.
Kobayashi E, Nakano H, Morimoto M et al. Calphostin C (UCN-1028 C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1989; 159: 548–53.
Sunitha I, Meighen DL, Hartman DP et al. Hepatocyte growth factor stimulates invasion across reconstituted basement membrens by a new human small intestinal cell line. Clin Exp Metastasis 1994; 12: 143–54.
Susa M, Keeler M, Varticovski L. Platelet-derived growth factor activates membrane-associated phosphatidylinositol 3–kinase and mediates its translocation from the cytosol. J Biol Chem 1992; 267: 22951–6.
Guguen-Guillouzo C, Campion JP, Brissot P et al. High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver. Cell Biol Int Rep 1982; 6: 625–8.
Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett 1991; 291: 229–32.
Shiota G, Rhoads DB, Wang TC et al. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1992; 89: 373–7.
Santoni-Rugiu E, Preisegger KH, Kiss A et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci USA 1996; 93: 9577–82.
Takayama H, La Rochelle WJ, Sharp R et al. Diverse tumorgenesis associated with aberrant development in mice over-expressing hepatocyte growth factor/ scatter factor. Proc Natl Acad Sci USA 1997; 94: 701–6.
Ueki T, Kaneda Y, Tsutsui H et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature Med 1999; 5: 226–30.
Pawson T, Schlessinger J. SH2 and SH3 domeins. Curr Biol 1993; 3: 434–42.
Egan SE, Weinberg RA. The pathway to signal achievement. Nature 1993; 365: 781–2.
Stolz DB, Michalopoulos GK. Comparative effects of hepatocyte growth factor and epidermal growth factor on motility, morphology, mitogenesis, and signal transduction of primary rat hepatocytes. J Cell Biochem 1994; 55: 445–64.
Adachi T, Nakashima S, Saji S et al. Mitogen-activated protein kinase activation in hepatocyte growth factor-stimulated hepatocytes: Involvement of protein tyrosine kinase and protein kinase C. Hepatology 1996; 23: 1244–53.
Hartman G, Weidner KM, Schwarz H et al. The motility signal of scatter factor/ hepatocyte growth factor mediated through the receptor tyrosine kinase Met requires intracellular action of Ras. J Biol Chem 1994; 269: 21936–9.
IIic D, Furuta Y, Kanazawa S et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995; 377: 539–44.
Amano M, Chihara K, Kimura K et al. Formation of actin stress fibers and focal adhesions enhancedby Rho-kinase. Science 1997; 275: 1308–11.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakanishi, K., Fujimoto, J., Ueki, T. et al. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. Clin Exp Metastasis 17, 507–514 (1999). https://doi.org/10.1023/A:1006685218766
Issue Date:
DOI: https://doi.org/10.1023/A:1006685218766